New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2013
11:03 EDTJEC, NWS, CACI, RSG, SGMOHigh option volume stocks: NWS SGMO CACI JEC RSG
News For NWS;SGMO;CACI;JEC;RSG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 20, 2015
07:10 EDTSGMOPiper Jaffray to hold a symposium
Subscribe for More Information
May 19, 2015
07:45 EDTJECJacobs Engineering receives contract from Bristol-Myers
Jacobs Engineering (JEC) received a contract from Bristol-Myers Squibb Company (BMY) to provide construction management services for a new large-scale biologics manufacturing facility in Cruiserath, County Dublin, Ireland. Jacobs is also providing architectural and engineering services for the facility, which is being built to produce multiple therapies for the company’s robust and growing portfolio of approved and investigational biologic medicines, and to increase Bristol-Myers Squibb’s biologics manufacturing capacity. The new facility is expected to include multiple large scale bioreactors, a purification area, as well as office and laboratory space. Bristol-Myers Squibb’s Board of Directors has approved initial funding that will support the first phase of the project, with the full cost of the facility expected to be finalized in the second half of 2015. The facility is estimated to be operational in 2019.
May 18, 2015
07:06 EDTSGMOSangamo presents new data from proprietary ZFP therapeutic programs
Subscribe for More Information
May 14, 2015
09:11 EDTSGMOSangamo updates HIV and cancer candidates results
Sangamo BioSciences announced clinical and preclinical data from several ZFP Therapeutic programs and collaborations demonstrating new evidence of viral control in HIV/AIDS. Two trials of the company's ZFP Therapeutic, SB-728-T, which is being developed as a potential 'functional cure' for HIV/AIDS, demonstrated the effect of SB-728-T treatment on both viral load control and HIV reservoir reduction in HIV-infected subjects. Data were also presented demonstrating the successful incorporation of ZFN-mediated genome editing into an existing clinical scale production method to improve the anti-tumor activity of a tumor infiltrating lymphocyte-based therapeutic for melanoma.
May 12, 2015
07:46 EDTJECJacobs Engineering providing EPCM services for Sadara Chemical Company
Subscribe for More Information
07:46 EDTJECJacobs Engineering awarded contract from EDF Energy for nuclear power stations
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use